Early studies indicated that WT1 is a tumor suppressor, as damage to both alleles results in Wilms' tumor. This tumor of the kidney seems to originate from a single mesenchymal stem cell whose proliferation should normally be switched off, but which instead apparently tries to reiterate the normal processes of kidney development. More recent studies suggest that WT1 is both a transcription regulator and a splicing factor, depending on the absence or presence, respectively, of the KTS region. WT1 may also have a role in post-transcriptional regulation. Thus, WT1 is a single gene with multiple functions depending on where, when and how it is expressed and processed.
The expression of WT1 in the developing urogenital system, coupled with the timing of its expression in the early embryo, and its involvement in sex-reversal in some cases, prompted Hossain and Saunders to investigate whether there might be a direct interaction between this gene and the sex-determining gene, SRY. SRY is the major genetic switch that causes the developing embryo to change course from the default female developmental pathway into the male pathway, and little is known about its regulation.
Hossain and Saunders used plasmid constructs of the SRY promoter to drive expression of the luciferase gene and cotransfected these together with WT1 expression constructs into various cell lines to discover whether the presence of one of the four isoforms of WT1 mentioned above could activate the SRY promoter. They also investigated whether any of the WT1 constructs could activate the endogenous SRY promoter in certain cell lines.
Key results
Activation of the SRY promoter was achieved by the WT1 constructs lacking KTS (-KTS), consistent with the proposed transcriptional activator activity of the -KTS isoforms. By assessing the transactivation of various SRY deletion constructs, the authors showed that the WT1-responsive element lay within the SRY promoter itself. To identify nucleotides essential for transactivation, they then altered nucleotides within the one putative WT1-responsive element found within the SRY promoter, and backed this up by gel-shift assays. They showed that this WT1-responsive element was essential for WT1 to bind to and transactivate the SRY promoter. They then made WT1 mutant constructs containing single point mutations known to cause Denys-Drash syndrome (DDS), and found that the most common mutations within the zinc-finger domain resulted in failure to transactivate the SRY promoter, whereas those outside this domain transactivated to the same degree as wild-type WT1. Finally, they showed that these mutants did not act in a dominant-negative fashion.
Conclusions
Using a candidate gene approach, Hossain and Saunders showed that SRY is a direct target of the WT1 protein. Many other genes have recently been shown to be upregulated by WT1, and none appears to be downregulated, suggesting that WT1 has a major role in upregulating gene expression in vivo. The hypothesis that single mutations resulting in DDS operated in a dominant-negative fashion is thrown into doubt by this work. The authors suggest a new model for the mechanism underlying DDS, in which haploinsufficiency reduces the ability of WT1 to activate transcription, thus affecting expression of critical downstream targets.
Reporter's comments
WT1 is a gene with several functions, depending on the context and manner of its expression. This work is therefore particularly topical, given the recent discovery that the human genome contains fewer genes than expected.
